Platform
We have developed a unique toolbox of platform capabilities designed to overcome the challenges and limitations of advanced gene therapy development and enabling in-vivo gene editing solutions.
Proprietary Engineered Heart Tissue (EHT) Technology
Based on Human-induced pluripotent stem cell cardiomyocytes, EHT creates a test bed for gene therapy with rapid translation into the clinic.
Proprietary Loco-Regional Perfusion (LRP) System
Delivers gene therapy directly to the heart tissue and other solid organs, limits systemic exposure, off-target effects and allows for repeat dosing.
